These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1574 related articles for article (PubMed ID: 31320594)

  • 1. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
    Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
    Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia.
    Tan Y; Xin L; Wang Q; Xu R; Tong X; Chen G; Ma L; Yang F; Jiang H; Zhang N; Wu J; Li X; Guo X; Wang C; Zhou H; Zhou F
    Cancer Lett; 2024 Jun; 592():216933. PubMed ID: 38705564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
    J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
    Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
    Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
    Garitano-Trojaola A; Sancho A; Götz R; Eiring P; Walz S; Jetani H; Gil-Pulido J; Da Via MC; Teufel E; Rhodes N; Haertle L; Arellano-Viera E; Tibes R; Rosenwald A; Rasche L; Hudecek M; Sauer M; Groll J; Einsele H; Kraus S; Kortüm MK
    Commun Biol; 2021 Jun; 4(1):799. PubMed ID: 34172833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of
    Wu S; Edwards H; Wang D; Liu S; Qiao X; Carter J; Wang Y; Taub JW; Wang G; Ge Y
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078163
    [No Abstract]   [Full Text] [Related]  

  • 10. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
    Janssen M; Schmidt C; Bruch PM; Blank MF; Rohde C; Waclawiczek A; Heid D; Renders S; Göllner S; Vierbaum L; Besenbeck B; Herbst SA; Knoll M; Kolb C; Przybylla A; Weidenauer K; Ludwig AK; Fabre M; Gu M; Schlenk RF; Stölzel F; Bornhäuser M; Röllig C; Platzbecker U; Baldus C; Serve H; Sauer T; Raffel S; Pabst C; Vassiliou G; Vick B; Jeremias I; Trumpp A; Krijgsveld J; Müller-Tidow C; Dietrich S
    Blood; 2022 Dec; 140(24):2594-2610. PubMed ID: 35857899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M; Shen C; Chen Y; Chen Z; Zhou K; Chen Y; Li W; Zeng C; Qing Y; Wu D; Xu C; Tang T; Che Y; Qin X; Xu Z; Wang K; Leung K; Sau L; Deng X; Hu J; Wu Y; Chen J
    Cell Rep Med; 2024 Jul; 5(7):101645. PubMed ID: 39019012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
    Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
    J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
    Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
    Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
    BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib.
    Ha YN; Song S; Orlikova-Boyer B; Cerella C; Christov C; Kijjoa A; Diederich M
    Mar Drugs; 2020 Jan; 18(1):. PubMed ID: 31963113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
    Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S
    Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
    McMahon CM; Perl AE
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 79.